Drug Trial Radar · NCT05216887
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Feb 1, 2022
Primary completion
Jul 27, 2022
Study completion Jul 27, 2022
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the pharmacokinetic (PK) comparability of 2 fixed subcutaneous (SC) doses of aducanumab with a single, weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of the study are to assess the safety and tolerability of aducanumab administered SC in healthy volunteers and to characterize additional PK parameters of 2 fixed SC doses of aducanumab and a single, weight-based IV dose of aducanumab.
Conditions
- Healthy Volunteer
Interventions
AducanumabBiological
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of AducanumabTime frame: Predose and at multiple time points post-dose up to Day 99
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials
Anaheim, California
QPS-MRA
Miami, Florida
QPS Missouri
Springfield, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.